Metastatic melanoma is not considered curable in the traditional sense, but a growing number of patients are living years or even decades after diagnosis with no detectable disease. The five-year survival rate for melanoma that has spread to distant organs is 34%, a figure that would have been unthinkable 15 years ago when it hovered in the single digits. Some of these long-term survivors show no signs of cancer returning, and while oncologists are cautious about using the word “cure,” many acknowledge that a subset of patients may never see their cancer come back.
Why Doctors Avoid the Word “Cure”
The National Cancer Institute defines a cure as no traces of cancer after treatment, with the cancer never returning. Remission, by contrast, means signs and symptoms have decreased or disappeared, but cancer cells could still be present. When someone achieves complete remission and stays there for five years or more, some doctors will cautiously use the word “cured.” But melanoma cells can linger in the body for years, and late recurrences do happen. For that reason, most oncologists prefer to say there are “no signs of cancer at this time” rather than guarantee it’s gone for good.
That distinction matters less than it sounds. If you reach five years with no evidence of disease, your chances of it returning drop significantly. And the longer you stay disease-free, the more your risk profile starts to resemble someone who never had metastatic melanoma at all. The practical difference between “cured” and “in durable complete remission for a decade” is, for many patients, academic.
How Immunotherapy Changed the Outlook
The single biggest reason metastatic melanoma survival has improved is immunotherapy, specifically checkpoint inhibitors that help your immune system recognize and attack cancer cells. Before these drugs became available around 2011, the median survival for stage IV melanoma was measured in months. Now, a meaningful percentage of patients are alive five, seven, even ten years later.
Combination immunotherapy, which pairs two checkpoint inhibitors together, produces the strongest results. In clinical trials, about 28% of patients who responded to the combination still had their response holding at the five-year mark. Even patients whose tumors had characteristics typically associated with worse outcomes saw durable responses lasting five years or more in roughly 21% of cases. The median duration of response for the combination approach was over 24 months, compared to under 7 months for older chemotherapy regimens.
Perhaps most encouraging is what happens when patients achieve a complete response, meaning scans show no remaining cancer. Data from the KEYNOTE-001 trial showed that nearly 90% of patients who reached complete response were still disease-free after a median follow-up of 3.5 years. Some of these patients had stopped treatment entirely, suggesting the immune system had learned to keep the cancer in check on its own.
Targeted Therapy for BRAF Mutations
About half of all melanomas carry a specific genetic mutation called BRAF. If your tumor has this mutation, you may be treated with drugs that directly block the signals driving cancer growth. These targeted therapies, typically a combination of two drugs that work on related pathways, produce rapid responses in many patients.
Five-year survival with combination targeted therapy sits at roughly 30% to 40%. The progression-free survival rate at four to five years is lower, around 15% to 21%, meaning most patients who respond will eventually see their cancer grow again. But here’s the key finding: patients who make it to four years without progression tend to stay that way. In one long-term follow-up study, over 75% of patients who were progression-free at four years maintained that response after nearly eight years of follow-up. Among 146 such patients, almost 90% were still alive at a median of 7.8 years from treatment start.
This creates a pattern oncologists describe as a “tail on the curve,” where the survival line flattens out rather than continuing to drop. The patients in that tail are, functionally, living with their melanoma as a past event rather than an ongoing disease.
Newer Options After Initial Treatment Fails
For patients whose melanoma progresses through standard immunotherapy and targeted therapy, additional options now exist. One is a cell-based therapy that uses your own immune cells, extracted from your tumor, grown in large numbers in a lab, and infused back into your body. This approach, approved in 2024, showed an overall response rate of about 31% in patients with advanced melanoma who had already tried other treatments. Complete responses, where all detectable cancer disappeared, occurred in roughly 6% of patients. While those numbers are modest, they represent real options for people who previously had none.
Factors That Influence Your Odds
Not everyone with metastatic melanoma faces the same prognosis. Several factors tilt the odds significantly in one direction or the other.
One of the strongest predictors is a blood marker called LDH. When LDH levels are elevated, it signals more aggressive disease and generally worse outcomes across all treatment types. In patients with high LDH treated with combination immunotherapy, the 12-month overall survival rate was 66%, compared to lower rates for those on single-agent treatments or targeted therapy alone. Combination immunotherapy appeared to partially offset the disadvantage of elevated LDH, but it remained a significant hurdle.
Where the cancer has spread also matters. Melanoma that reaches the brain, liver, or bone tends to be harder to control than disease limited to the lungs or soft tissue. The number of organs involved plays a role too. Patients with limited metastatic disease, meaning fewer spots in fewer locations, consistently do better than those with widespread involvement.
Your overall health, age, and how well you tolerate treatment all factor in. Patients who can receive full-dose combination immunotherapy and manage the side effects generally have the best chance of a durable response.
What Happens When Treatment Stops
One question that comes up frequently is whether you need to stay on treatment forever. The answer, increasingly, is no. Research shows that many patients who achieve a strong response can safely stop immunotherapy without their cancer returning. In one study, patients treated for a median of about 11 months were followed after electively stopping treatment. Among those who had achieved complete response, 75% remained progression-free at nearly 21 months of follow-up.
Some data even suggests that stopping treatment at certain time points may lead to outcomes as good as or better than continuing indefinitely. One analysis found that patients who discontinued treatment at 24 months had an absolute survival advantage of about 10% at four years compared to those who continued. This likely reflects the fact that patients doing well enough to stop are already in a favorable position, but it also shows that indefinite treatment isn’t always necessary.
Monitoring After Remission
If you achieve remission from stage IV melanoma, you’ll enter a structured follow-up schedule designed to catch any recurrence early. Current guidelines recommend physical exams focused on the skin and lymph nodes every three to six months for the first two years, then every three to twelve months for years three through five. Imaging scans follow a similar pattern, typically every three to twelve months for two years, then every six to twelve months for the next three years. After five years with no recurrence, routine imaging is generally no longer recommended, though annual skin checks continue.
This tapering schedule reflects the reality that most recurrences happen within the first few years. Each year that passes without a return of cancer makes the next year safer. For patients who reach the five-year mark with no evidence of disease, the monitoring shifts from active surveillance to routine cancer screening, much like anyone else’s.
The Honest Answer
Metastatic melanoma is not yet reliably curable for most patients. But it is curable for some, and the percentage of people achieving what looks like a permanent remission continues to grow. Roughly one in three patients with distant-stage melanoma is alive at five years, and many of those survivors show no signs of active disease. The combination of immunotherapy, targeted therapy, and newer cell-based treatments has turned what was once a near-certain death sentence into a disease where long-term survival is a realistic possibility. The gap between “we can’t call it a cure” and “your cancer appears to be gone” is one that thousands of patients are living in right now.